Bimzelx is a biologic that was approved for the treatment of moderate-to-severe plaque psoriasis in 2023.
Bimzelx (also known by its generic name bimekizumab-bkzx) was approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Bimzelx is given by injection. For adults with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment), weeks 4, 8, 12, and 16, and then every 8 weeks afterward.
To learn more, please visit the Bimzelx website.
Get the latest news on new treatment options from NPF.Stay up to date
FDA Approves BIMZELX®
The first biologic targeting IL-17A and IL-17F is now approved for adults with moderate to severe plaque psoriasis.Read More
Learn More About Your Treatment Options
Contact a Patient Navigator today
The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.